Evogen

History

2022: Receiving a grant of 277.6 million rubles from Moscow

At the end of May 2022, Evogen received a grant of 277.6 million rubles from the Moscow City Hall for scientific research to introduce innovative methods of treating oncological diseases caused by hereditary tumor syndromes into the practice of metropolitan healthcare.

By the end of May 2022, a scientific study of genetic mutations in patients with the first detected malignancies of the breast, ovaries and colorectal cancer is underway in Moscow . It also includes relatives of patients who, according to the results of an oncogenetic test, revealed hereditary tumor syndrome.

Moscow Mayor's Office allocated 277.6 million rubles to Evogen for genetic research on cancer

Six oncological centers are involved in the study: the A.S. Loginov Moscow Clinical Research Center, Moscow City Cancer Hospital No. 62, City Clinical Cancer Hospital No. 1, S.P. Botkin City Clinical Hospital, Kommunarka Moscow Multidisciplinary Clinical Center and D.D. Pletnev City Clinical Hospital.

The results of research will be the development of a system of preventive surveillance of patients and their relatives with the aim of early diagnosis of oncological diseases due to heredity.

The Moscow government also sent Evogen 311 million rubles to continue at the end of 2022 and in 2023 to conduct non-invasive prenatal testing (NIPT) of pregnant women to detect chromosomal abnormalities in fetal development. Evogen has been participating in this project since October 2021. It is assumed that the grant will allow the introduction of additional highly reliable molecular genetic research methods into the metropolitan health system, allowing for confirmation of the diagnosis within two to three days.^[1]

Notes